{"product_id":"phg-bcg-matrix","title":"(PHG) Koninklijke Philips N.V. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Koninklijke Philips N.V. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and decision-making. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMRI, CT and spectral CT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhilips' MRI, CT and spectral CT line sits in a hospital upgrade cycle that keeps demand for high-ticket imaging high. These are premium systems with recurring service revenue, so each installed base adds long-tail cash flow. The business also needs steady R\u0026amp;D and sales spend, which fits a Star in BCG terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltrasound systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltrasound systems fit Star status: demand keeps rising in cardiology, general imaging, OB\/GYN, and point-of-care care, and Philips pairs scanners with software, not just hardware. Philips reported 2025 sales of €18.0 billion, showing it has scale to fund this growing category. With a broad clinical footprint and an expanding market, ultrasound can still absorb investment while scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImage-guided therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImage-guided therapy is a Star for Koninklijke Philips N.V. because it sits in a fast-growing, high-value market tied to minimally invasive care and hospital upgrades. In Philips 2025 results, the Image-Guided Therapy segment generated strong sales and keeps earning repeat revenue from installation, software, and lifecycle services, not just one-off equipment deals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcute patient monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcute patient monitoring fits the Star quadrant because connected ICU and ward monitoring stays central as hospitals move to digital, continuous care. Philips had 2024 sales of €18.0 billion, and this segment benefits from a large installed base that supports recurring upgrades and service revenue. Still, Philips must keep spending to defend share and refresh aging systems. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge installed base supports share\u003c\/li\u003e\n\u003cli\u003eDigital monitoring demand keeps rising\u003c\/li\u003e\n\u003cli\u003eUpgrade spend is still needed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSleep and respiratory care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSleep and respiratory care fits Stars because it serves a large chronic-care base that needs home use, repeat supplies, and ongoing clinical support. Philips still has strong brand reach in CPAP and ventilation, so this unit can keep scaling if demand stays firm, but it also carries heavy service and compliance costs after the recall shock. That mix makes it more of a growth asset than a cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume, repeat-use care\u003c\/li\u003e\n\u003cli\u003eBrand still supports share\u003c\/li\u003e\n\u003cli\u003eSupport costs stay high\u003c\/li\u003e\n\u003cli\u003eGrowth can offset spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhilips’ Star Businesses: MRI, CT, Ultrasound, and More\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKoninklijke Philips N.V.'s Stars are MRI, CT, spectral CT, ultrasound, image-guided therapy, and acute monitoring. In 2025, Philips reported €18.0 billion in sales, and these units gain from hospital upgrade cycles, recurring service income, and digital care demand. Sleep and respiratory care also has Star traits, but recall-related costs still weigh on it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar area\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI, CT, spectral CT\u003c\/td\u003e\n\u003ctd\u003eHigh-ticket upgrades, service revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUltrasound\u003c\/td\u003e\n\u003ctd\u003eBroad clinical demand, software tie-ins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImage-guided therapy\u003c\/td\u003e\n\u003ctd\u003eMinimally invasive growth, repeat revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute monitoring\u003c\/td\u003e\n\u003ctd\u003eConnected ICU demand, upgrade cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePhilips BCG Matrix maps its businesses to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Philips BCG Matrix that quickly shows each business unit’s quadrant to reduce strategic planning guesswork\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists credible sources behind Koninklijke Philips N.V. assumptions, making the analysis easier to verify, trust, and use in decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSonicare electric toothbrushes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSonicare electric toothbrushes fit the Cash Cows box: a mature oral-care category with strong brand recall and steady demand. Replacement cycles are usually about 1–2 years, so sales repeat with limited new-market spend. That lets Koninklijke Philips N.V. keep cash generation high while investing less in growth than in newer segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReplacement brush heads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReplacement brush heads fit Philips’ cash-cow profile: they drive repeat buys and usually carry better margins than the handle itself. Philips reported 2024 group sales of about €18.0 billion, and its large Sonicare user base supports steady replenishment demand even in a mature oral-care market. That makes this a classic installed-base, recurring-revenue business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhilips Avent infant feeding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhilips Avent infant feeding is a mature, globally sold line with steady demand from parents and retailers, so it fits the Cash Cow slot in Koninklijke Philips N.V.'s BCG mix. It grows slower than medical technology, but its trusted brand keeps volume stable and supports repeat sales with modest marketing and product spend. That makes it a good cash generator that can help fund higher-growth segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNorelco male grooming\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNorelco male grooming sits in a mature shavers-and-trimmers market, so growth is slower than in Philips’ health-tech lines. Philips’ long brand equity and wide retail reach keep it a steady seller, which fits a Cash Cows role in the BCG Matrix.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, Philips kept generating strong cash from Personal Health, and grooming benefits from repeat purchases and low need for heavy capex. That makes it more of a dependable cash engine than a high-growth bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e成熟 market, low growth\u003c\/li\u003e\n\u003cli\u003eStrong Philips brand support\u003c\/li\u003e\n\u003cli\u003eBroad store and online reach\u003c\/li\u003e\n\u003cli\u003eRepeat buys drive cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled-base service contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstalled-base service contracts are a classic cash cow for Koninklijke Philips N.V. because service, maintenance, and upgrades on imaging and patient-care systems keep revenue recurring after the initial sale. In 2024, Philips reported about €18.0 billion in sales, and this large hospital footprint helps support steady, high-repeat service income with stronger margins than new equipment sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue from installed systems\u003c\/li\u003e\n\u003cli\u003eLarge base in hospitals\u003c\/li\u003e\n\u003cli\u003eLow growth, high repeat demand\u003c\/li\u003e\n\u003cli\u003eStrong margin, cash-generating profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhilips’ Cash Cows: Repeat Revenue From Trusted Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSonicare, replacement brush heads, Avent, Norelco, and installed-base service contracts fit Cash Cows because they sit in mature markets, sell on repeat, and need limited growth spend. Philips reported about €18.0 billion in 2024 sales, and these lines help turn that installed base into steady cash in FY2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow driver\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSonicare and brush heads\u003c\/td\u003e\n\u003ctd\u003eRepeat buys, mature category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvent and Norelco\u003c\/td\u003e\n\u003ctd\u003eStable demand, strong brand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled-base service\u003c\/td\u003e\n\u003ctd\u003eRecurring, higher-margin revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhilips sales\u003c\/td\u003e\n\u003ctd\u003eAbout €18.0 billion in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eKoninklijke Philips N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Koninklijke Philips N.V. BCG Matrix document you’ll receive after purchase. No demo content or placeholder pages—just the full, ready-to-use report. Once purchased, the same file is available for immediate download, printing, or presentation. It’s designed to give you clear strategic insight from the start.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeeth whitening kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeeth whitening kits are a crowded, low-differentiation niche, so this fits a Dog in Koninklijke Philips N.V.'s BCG Matrix. Growth is modest versus Philips' core HealthTech engine, which sits on a much larger multibillion-euro revenue base. This category is best managed for efficiency, cash discipline, and selective SKU pruning, not aggressive expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterdental cleaning aids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInterdental cleaning aids sit in a mature oral-care niche, and Philips does not seem to have the same scale edge here as in electric toothbrushes and brush heads. Low growth and weak pricing power point to a Dog in the BCG Matrix. In Philips’ 2025 portfolio mix, this kind of subcategory is unlikely to add much to profit growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy EMR modules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy EMR modules sit in Philips' Dogs bucket: healthcare software is crowded, and Philips' 2025 filings still do not show it as a standalone growth engine, unlike imaging and devices. With Epic and Oracle Health setting the pace, these older modules stay low-share and low-growth.\u003c\/p\u003e\n\u003cp\u003eSo they look like capital traps unless Philips can lift share or fold them into larger workflows. The one-line read: keep only the parts that support installed base and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-end beauty devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-end beauty devices sit in the Dogs bucket for Koninklijke Philips N.V. because the category is heavily commoditized, so pricing is weak and margins stay under pressure. Philips’ brand still carries more weight in core oral care than in lower-end beauty SKUs, and these lines are unlikely to deliver meaningful growth or market-share gains.\u003c\/p\u003e\n\u003cp\u003eThat makes them a capital-light hold at best, not a growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh commoditization\u003c\/li\u003e\n\u003cli\u003eWeak pricing power\u003c\/li\u003e\n\u003cli\u003eOral care is stronger\u003c\/li\u003e\n\u003cli\u003eLow growth upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManual oral-care lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManual brushes and basic oral-care items sit in Koninklijke Philips N.V.’s mature end of Oral Healthcare: low ticket size, limited differentiation, and no built-in upgrade cycle. Philips reported 2024 group sales of EUR 18.0 billion, with Personal Health under pressure, while connected Sonicare products support higher-margin repeat demand. So these manual lines look more like cash traps than growth assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-margin, mature category\u003c\/li\u003e\n\u003cli\u003eNo recurring upgrade cycle\u003c\/li\u003e\n\u003cli\u003eWeak fit for growth BCG view\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhilips’ Dogs: Small, Slow, and Mostly Cash-Flow Cattle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Koninklijke Philips N.V. are low-share, low-growth lines like manual oral-care and legacy software. Philips reported EUR 18.0 billion 2024 sales, but these niches lack the scale or pricing power to move profit. Keep them for cash, installed-base support, and only prune what drags returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog segment\u003c\/th\u003e\n\u003cth\u003e2025\/2024 cue\u003c\/th\u003e\n\u003cth\u003eRead\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual oral care\u003c\/td\u003e\n\u003ctd\u003eLow margin\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy EMR modules\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital pathology AI with Ibex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhilips’ digital pathology AI with Ibex fits a fast-growing market, with global digital pathology set to expand sharply as cancer volumes rise to 35 million cases by 2050, from 20 million in 2022. Philips is still a partner, not a leader, so it is building share through Ibex rather than owning the field. That makes it a Question Mark: attractive upside, but market position is still being formed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNICO.LAB stroke AI collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStroke care is a big need: the World Stroke Organization says about 12.2 million people have a stroke each year, and fast triage can cut delays. Philips’ NICO.LAB collaboration uses AI-assisted workflow to enter this niche, but it is still a partnership-led, early-stage bet. That makes it a question mark: high potential, yet still unproven in scaled adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCare management platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCare management platforms sit in Philips’ Question Marks: hospitals are digitizing pathways, so software-led care coordination is growing. Philips has a strong healthcare brand and broad installed base, but the field is crowded with Epic, Oracle Health, and Siemens Healthineers, so share is not easy to win. It needs focused investment now to turn demand into scale and lift its low-share position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnterprise diagnostic informatics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnterprise diagnostic informatics should benefit as imaging volume and hospital digitization rise; over 96% of U.S. non-federal acute care hospitals already use certified EHRs, and imaging demand keeps pushing data workflows. Philips has products here, but software platforms scale slower than devices, so this looks like a classic invest-or-trim Question Mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth tied to imaging and digitization\u003c\/li\u003e\n\u003cli\u003eSoftware is harder to scale\u003c\/li\u003e\n\u003cli\u003eLikely needs selective investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCloud-connected workflow software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCloud-connected workflow software sits in a fast-growing connected-hospital market, and Philips can sell it with its devices and services. Still, standalone share is not yet proven, so the unit needs more spending and adoption before it can move from Question Mark to Star. Philips reported €18.0 billion in 2024 sales, which gives it scale to fund the push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing hospital cloud demand\u003c\/li\u003e\n\u003cli\u003eBundle with Philips devices\u003c\/li\u003e\n\u003cli\u003eStandalone share still low\u003c\/li\u003e\n\u003cli\u003eNeeds funding and adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhilips’ Software Bets Target Big Markets, But Share Remains Low\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhilips’ Question Marks are software-led bets with clear demand but weak share: digital pathology AI, stroke workflow, care management, and cloud-connected informatics. They sit in growing markets, but adoption is still early, so Philips must keep funding to turn platform reach into scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital pathology AI\u003c\/td\u003e\n\u003ctd\u003eCancer cases may reach 35m by 2050\u003c\/td\u003e\n\u003ctd\u003eHigh growth, low share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStroke AI\u003c\/td\u003e\n\u003ctd\u003e12.2m strokes a year\u003c\/td\u003e\n\u003ctd\u003eEarly-stage partnership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare management\u003c\/td\u003e\n\u003ctd\u003e96%+ U.S. hospitals use EHRs\u003c\/td\u003e\n\u003ctd\u003eCrowded, needs investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhilips scale\u003c\/td\u003e\n\u003ctd\u003e€18.0bn sales in 2024\u003c\/td\u003e\n\u003ctd\u003eCan fund the push\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234883903753,"sku":"phg-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/phg-bcg-matrix.webp?v=1785728568","url":"https:\/\/dcfanalyst.com\/products\/phg-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}